17 results on '"De novo hepatitis"'
Search Results
2. Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis
- Author
-
Kento Inada, Shun Kaneko, Masayuki Kurosaki, Koji Yamashita, Sakura Kirino, Leona Osawa, Yuka Hayakawa, Shuhei Sekiguchi, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Nobuharu Tamaki, Yutaka Yasui, Jun Itakura, Yuka Takahashi, Kaoru Tsuchiya, Hiroyuki Nakanishi, Ryuichi Okamoto, and Namiki Izumi
- Subjects
de novo hepatitis ,hepatitis B virus reactivation ,tenofovir alafenamide ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Background and Aim Administration of tenofovir alafenamide (TAF) as prevention or treatment of hepatitis B virus (HBV) reactivation is not well known. The aim of this study is to reveal the efficacy and safety of TAF against HBV reactivation. Methods Entecavir (ETV) and TAF were given to 66 and 11 patients, respectively, as prophylaxis against or treatment of HBV reactivation during chemotherapy or immune suppression therapy from January 2010 to June 2020. The antiviral effects and safety were assessed. Results At week 24, the antiviral effects on patients receiving ETV and TAF were similar in terms of reduction of HBV DNA (−2.83 ± 1.45log IU/mL vs −3.05 ± 2.47log IU/mL; P = 0.857) and achieving undetectable levels of HBV DNA (78.8 vs 90.9%; P = 0.681). There was no significant difference in the decrease in the estimated glomerular filtration rate (eGFR) between the two groups (−0.62 ± 11.2 mL/min/1.73 m2 vs −3.67 ± 13.2 mL/min/1.73 m2; P = 0.291). Conclusion TAF is safe and effective against HBV reactivation.
- Published
- 2021
- Full Text
- View/download PDF
3. Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis.
- Author
-
Inada, Kento, Kaneko, Shun, Kurosaki, Masayuki, Yamashita, Koji, Kirino, Sakura, Osawa, Leona, Hayakawa, Yuka, Sekiguchi, Shuhei, Higuchi, Mayu, Takaura, Kenta, Maeyashiki, Chiaki, Tamaki, Nobuharu, Yasui, Yutaka, Itakura, Jun, Takahashi, Yuka, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Okamoto, Ryuichi, and Izumi, Namiki
- Subjects
HEPATITIS B virus ,VIRUS reactivation ,TENOFOVIR ,GLOMERULAR filtration rate ,HEPATITIS - Abstract
Background and Aim: Administration of tenofovir alafenamide (TAF) as prevention or treatment of hepatitis B virus (HBV) reactivation is not well known. The aim of this study is to reveal the efficacy and safety of TAF against HBV reactivation. Methods: Entecavir (ETV) and TAF were given to 66 and 11 patients, respectively, as prophylaxis against or treatment of HBV reactivation during chemotherapy or immune suppression therapy from January 2010 to June 2020. The antiviral effects and safety were assessed. Results: At week 24, the antiviral effects on patients receiving ETV and TAF were similar in terms of reduction of HBV DNA (−2.83 ± 1.45log IU/mL vs −3.05 ± 2.47log IU/mL; P = 0.857) and achieving undetectable levels of HBV DNA (78.8 vs 90.9%; P = 0.681). There was no significant difference in the decrease in the estimated glomerular filtration rate (eGFR) between the two groups (−0.62 ± 11.2 mL/min/1.73 m2vs −3.67 ± 13.2 mL/min/1.73 m2; P = 0.291). Conclusion: TAF is safe and effective against HBV reactivation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection.
- Author
-
Kotake, Takeshi, Satake, Hironaga, Okita, Yoshihiro, Hatachi, Yukimasa, Hamada, Mamiko, Omiya, Masatomo, Yasui, Hisateru, Hashida, Toru, Kaihara, Satoshi, Inokuma, Tetsuro, and Tsuji, Akihito
- Subjects
- *
HEPATITIS B virus , *CANCER chemotherapy , *LIVER diseases , *HEPATITIS associated antigen , *TUMORS - Abstract
Background: Reports of hepatitis B virus (HBV) reactivation in solid tumors are very limited, and their frequencies and risk factors were previously unknown. Aim: To evaluate the prevalence and risk factors of HBV reactivation in patients with solid tumors with resolved HBV infection. Methods: All 1088 patients with solid tumors were assessed for eligibility; 251 patients had resolved HBV infection (negative for HBs antigen and positive for anti‐HBc antibody and/or positive for anti‐HBs antibody), and HBV‐DNA was assessed for 243 of these patients in whom we analyzed the prevalence of HBV reactivation. Risk factors for HBV reactivation were exploratorily evaluated by analysis of a case–control study. Results: The prevalence of HBV‐DNA reactivation was 2.1% (95% confidence interval [CI], 0.3–3.9%). We did not observe any exacerbation of HBV‐DNA by early intervention. A low anti‐HBs antibody titer (<10.0 mIU/mL) and high average daily dexamethasone dose (>1.0 mg/day) were high risk factors, with odds ratios of 5.94 (95% CI, 1.15–30.6, P = 0.03) and 8.69 (95% CI, 1.27–58.8, P = 0.02), respectively. Conclusion: HBV reactivation in solid tumor patients was relatively rare. Therefore, risk factors that can identify targets for HBV screening must be determined in future studies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis
- Author
-
Ryuichi Okamoto, Kenta Takaura, Koji Yamashita, Yuka Takahashi, Masayuki Kurosaki, Nobuharu Tamaki, Leona Osawa, Kaoru Tsuchiya, Hiroyuki Nakanishi, Shun Kaneko, Chiaki Maeyashiki, Sakura Kirino, Yuka Hayakawa, Yutaka Yasui, Mayu Higuchi, Shuhei Sekiguchi, Jun Itakura, Kento Inada, and Namiki Izumi
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Renal function ,RC799-869 ,medicine.disease_cause ,Tenofovir alafenamide ,Gastroenterology ,Immune system ,Internal medicine ,medicine ,de novo hepatitis ,tenofovir alafenamide ,Hepatitis ,Hepatitis B virus ,Chemotherapy ,Hepatology ,business.industry ,Significant difference ,Original Articles ,Entecavir ,Diseases of the digestive system. Gastroenterology ,medicine.disease ,hepatitis B virus reactivation ,Original Article ,business ,medicine.drug - Abstract
Background and Aim Administration of tenofovir alafenamide (TAF) as prevention or treatment of hepatitis B virus (HBV) reactivation is not well known. The aim of this study is to reveal the efficacy and safety of TAF against HBV reactivation. Methods Entecavir (ETV) and TAF were given to 66 and 11 patients, respectively, as prophylaxis against or treatment of HBV reactivation during chemotherapy or immune suppression therapy from January 2010 to June 2020. The antiviral effects and safety were assessed. Results At week 24, the antiviral effects on patients receiving ETV and TAF were similar in terms of reduction of HBV DNA (−2.83 ± 1.45log IU/mL vs −3.05 ± 2.47log IU/mL; P = 0.857) and achieving undetectable levels of HBV DNA (78.8 vs 90.9%; P = 0.681). There was no significant difference in the decrease in the estimated glomerular filtration rate (eGFR) between the two groups (−0.62 ± 11.2 mL/min/1.73 m2 vs −3.67 ± 13.2 mL/min/1.73 m2; P = 0.291). Conclusion TAF is safe and effective against HBV reactivation., The aim of this study is to reveal the efficacy and safety of tenofovir alafenamide (TAF) as prophylaxis against or treatment of hepatitis B virus (HBV) reactivation. The antiviral effects in terms of HBV DNA reduction on patients receiving entecavir and TAF were similar, and there was no significant difference in renal dysfunction between both groups. TAF is safe and effective against HBV reactivation.
- Published
- 2021
6. Adult Living Donor Liver Transplantation Using Hepatitis B Core Antibody-Positive Grafts in Korea, a Hepatitis B-endemic Region
- Subjects
de novo hepatitis ,hepatitis b core antibody ,liver transplantation ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background/AimsThe exclusion of hepatitis B core antibody (HBcAb)-positive donors from liver transplants (LTs) due to the risk of transmitting hepatitis B virus (HBV) does not appear to be practical in Korea, where hepatitis B is endemic. This study assessed the risk of de novo HBV infection in hepatitis B surface antigen (HBsAg)-negative LT recipients receiving a liver from HBcAb-positive donors.Methods : Of 341 adult living donor LTs conducted at our institution between March 2001 and September 2008, 176 donors (51.6%) were HBcAb-positive, and 26 HBcAb-positive grafts were transplanted to HBsAg-negative recipients. The median follow-up time after LT was 41.9 months.Results : Without anti-HBV prophylaxis, 2 out of 26 (7.7%) HBsAg-negative recipients who received grafts from HBcAb-positive donors developed de novo HBV infection 20 and 85 months after LT. These patients had been negative for all HBV serologic markers before transplantation. In both cases, there were no abnormalities in liver function tests upon diagnosis of de novo HBV infection.Conclusion : sDe novo HBV infection from HBcAb-positive donors after LT does not appear to be of great concern in terms of the number of cases in Korea because high risk patients who are HBV-negative comprise only a small proportion of the recipients. However, HBV-na?ve LT recipients still carry the risk of developing de novo HBV infection as in non-HBV endemic areas.
- Published
- 2011
- Full Text
- View/download PDF
7. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
- Author
-
Nakamura, Jun, Nagashima, Takao, Nagatani, Katsuya, Yoshio, Taku, Iwamoto, Masahiro, and Minota, Seiji
- Subjects
- *
RHEUMATOID arthritis treatment , *ANTIRHEUMATIC agents , *HEPATITIS B , *DNA analysis , *IMMUNOGLOBULINS , *DISEASE risk factors - Abstract
Objective: To examine the incidence of hepatitis B virus (HBV) reactivation in patients with rheumatoid arthritis (RA) receiving biological disease-modifying antirheumatic drugs (DMARDs). Methods: We retrospectively reviewed RA patients treated with biological DMARDs at our institution from July 2010 to December 2012. Patients with antibodies for hepatitis B core antigen and/or hepatitis B surface antigen were regarded as having prior HBV infection. Clinical data on these patients, including HBV-DNA levels, were retrieved from the medical records. Results: During the study period, 251 patients were administered various biological DMARDs. Six patients with a history of HBV vaccination and one patient with positive HBV surface antigen were excluded from the study. Fifty-seven of the remaining 244 patients (23.4%) had prior HBV infection. These patients were followed for a median of 18 months (range: 2-27 months) and HBV-DNA was examined a median of seven times (range: 2- 27). HBV-DNA was detected in three patients (5.3%), comprising two receiving tocilizumab and one receiving etanercept. However, HBV-DNA levels were below the quantitation limit (<2.1 log copies mL 1) in all three patients. HBV-DNA became negative again within several months in all three patients, while biological DMARDs were continued and liver function tests remained normal throughout. Conclusion: HBV-DNA reactivation occurred in 5.3% of RA patients with prior HBV infection during treatment with biological DMARDs, but there were no associated clinical manifestations. Accordingly, it seems that biological DMARDs can be used safely in patients with RA. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. Horizontal transmission of de novo hepatitis B between spouses: A case report.
- Author
-
Mawatari, Seiichi, Uto, Hirofumi, Moriuchi, Akihiro, Tabu, Kazuaki, Muromachi, Kaori, Tabu, Eriko, Oda, Kohei, Imanaka, Dai, Oshige, Akihiko, Nakazawa, Junichi, Kumagai, Kotaro, Tamai, Tsutomu, Okamoto, Hiroaki, Tsubouchi, Hirohito, and Ido, Akio
- Subjects
- *
HEPATITIS B transmission , *HEPATITIS B treatment , *HEPATITIS B , *VIRUS reactivation , *IMMUNOSUPPRESSIVE agents , *PATIENTS - Abstract
We report a female patient with acute hepatitis B due to horizontal transmission of hepatitis B virus from her husband, who suffered from de novo hepatitis B. A 48-year-old man underwent peripheral blood stem cell transplantation ( PBSCT) for adult T-cell leukemia/lymphoma. Nine months after the initial treatment, he was referred to our hospital because of jaundice. Laboratory data showed elevated serum aminotransferase levels and hepatitis B surface antigen ( HBsAg) positivity. We diagnosed de novo hepatitis B because a pre- PBSCT serum sample was negative for HBsAg and positive for anti-hepatitis B core antibody ( HBcAb). His liver function improved with entecavir therapy. Two months after his diagnosis of hepatitis B, his 31-year-old wife was admitted with fever and appetite loss. She was diagnosed with acute hepatitis B because of increased serum aminotransferase levels and HBsAg and immunoglobulin M HBcAb positivity. Sequencing of HBV DNA in the serum obtained from both patients showed 99.9% homology. Therefore, we diagnosed her acute hepatitis B as due to horizontal transmission of de novo hepatitis B from her husband. HBV derived from de novo hepatitis B should be considered a potential source of infection, although intrafamilial transmission of de novo hepatitis B is rare. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma
- Author
-
Akihiro Nagata, Kohei Oka, Takashi Okuda, Naoto Iwai, Yutaka Inada, Tasuku Hara, Toshiyuki Komaki, Toshifumi Tsuji, and Keizo Kagawa
- Subjects
Male ,medicine.medical_specialty ,Hepatitis B virus ,medicine.medical_treatment ,Case Report ,030204 cardiovascular system & hematology ,medicine.disease_cause ,Tenofovir alafenamide ,Gastroenterology ,Malignant lymphoma ,03 medical and health sciences ,0302 clinical medicine ,rituximab ,Internal medicine ,Internal Medicine ,medicine ,Humans ,de novo hepatitis ,Chemotherapy ,Peripheral Blood Stem Cell Transplantation ,Hepatitis B Surface Antigens ,business.industry ,virus diseases ,General Medicine ,Middle Aged ,medicine.disease ,Hepatitis B ,digestive system diseases ,Lymphoma ,hepatitis B virus reactivation ,030211 gastroenterology & hepatology ,Rituximab ,Female ,Virus Activation ,Liver function ,business ,medicine.drug - Abstract
A 54-year-old woman underwent chemotherapy including rituximab and autologous peripheral blood stem cell transplantation (auto-PBSCT) for diffuse large B-cell lymphoma. Before the treatment, she exhibited a resolved hepatitis B virus (HBV) infection. She was diagnosed with HBV reactivation based on positive serum HBV-DNA test results, 55 months after her last treatment. Subsequently, he was treated with tenofovir alafenamide fumarate (TAF) therapy and her liver function improved. Patients undergoing chemotherapy including rituximab and auto-PBSCT are at a high risk of HBV reactivation. In such cases, careful and long-term observations may be required to detect HBV reactivation.
- Published
- 2020
10. Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection
- Author
-
Yoshihiro Okita, Hisateru Yasui, Masatomo Omiya, Mamiko Hamada, Satoshi Kaihara, Tetsuro Inokuma, Yukimasa Hatachi, Hironaga Satake, Akihito Tsuji, Toru Hashida, and Takeshi Kotake
- Subjects
Male ,Exacerbation ,medicine.disease_cause ,Gastroenterology ,0302 clinical medicine ,Japan ,Risk Factors ,Neoplasms ,Prevalence ,030212 general & internal medicine ,Aged, 80 and over ,biology ,steroid ,Antibody titer ,virus diseases ,General Medicine ,Hepatitis B ,Middle Aged ,Oncology ,030220 oncology & carcinogenesis ,Original Article ,Female ,Antibody ,Adult ,medicine.medical_specialty ,Hepatitis B virus ,Antiviral Agents ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,de novo hepatitis ,Aged ,Retrospective Studies ,business.industry ,HBs antibody ,Case-control study ,Retrospective cohort study ,Odds ratio ,Original Articles ,medicine.disease ,resolved HBV infection ,digestive system diseases ,Case-Control Studies ,biology.protein ,solid tumor ,Virus Activation ,business - Abstract
Background Reports of hepatitis B virus (HBV) reactivation in solid tumors are very limited, and their frequencies and risk factors were previously unknown. Aim To evaluate the prevalence and risk factors of HBV reactivation in patients with solid tumors with resolved HBV infection. Methods All 1088 patients with solid tumors were assessed for eligibility; 251 patients had resolved HBV infection (negative for HBs antigen and positive for anti‐HBc antibody and/or positive for anti‐HBs antibody), and HBV‐DNA was assessed for 243 of these patients in whom we analyzed the prevalence of HBV reactivation. Risk factors for HBV reactivation were exploratorily evaluated by analysis of a case–control study. Results The prevalence of HBV‐DNA reactivation was 2.1% (95% confidence interval [CI], 0.3–3.9%). We did not observe any exacerbation of HBV‐DNA by early intervention. A low anti‐HBs antibody titer (1.0 mg/day) were high risk factors, with odds ratios of 5.94 (95% CI, 1.15–30.6, P = 0.03) and 8.69 (95% CI, 1.27–58.8, P = 0.02), respectively. Conclusion HBV reactivation in solid tumor patients was relatively rare. Therefore, risk factors that can identify targets for HBV screening must be determined in future studies.
- Published
- 2018
11. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy.
- Author
-
Oketani, Makoto, Ido, Akio, Uto, Hirofumi, and Tsubouchi, Hirohito
- Subjects
- *
HEPATITIS B prevention , *IMMUNOSUPPRESSIVE agents , *DRUG therapy , *LYMPHOMAS , *STEROID drugs , *NUCLEOSIDES , *RHEUMATOLOGY - Abstract
With the increasing use of potent immunosuppressive therapy, reactivation of hepatitis B virus (HBV) in endemic regions is becoming a clinical problem requiring special attention. A recent annual nationwide survey clarified that HBV reactivation related to immunosuppressive therapy has been increasing in patients with malignant lymphoma, other hematological malignancies, oncological or rheumatological disease. In the survey, rituximab plus steroid-containing chemotherapy was identified as a risk factor for HBV reactivation in hepatitis B surface antigen (HBsAg) negative patients with malignant lymphoma. In this setting, HBV reactivation resulted in fatal fulminant hepatitis regardless of the treatment of nucleoside analog. The Intractable Hepatobiliary Disease Study Group and the Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis jointly developed guidelines for preventing HBV reactivation. The essential features of the guideline are as follows. All patients should be screened for HBsAg by a sensitive method before the start of immunosuppressive therapy. Second, hepatitis B core antigen (HBcAb) and hepatitis B surface antibody (HBsAb) testing should be performed in HBsAg negative patients, especially those receiving intensive immunosuppressive therapy. Prophylaxis with nucleoside analogs is essential for preventing HBV reactivation in HBsAg positive patients. In contrast, HBsAg negative with HBcAb and/or HBsAb positive patients should be monitored monthly for an increase in serum HBV DNA during and 12 months after completion of chemotherapy. Nucleoside analogs should be administrated immediately when HBV DNA becomes positive during this period. This strategy facilitates commencement of nucleoside analogs at an early stage of HBV reactivation and results in prevention of severe hepatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
12. History and prevention of de novo hepatitis B virus-related hepatitis in Japan and the world.
- Author
-
Tanaka, Eiji and Umemura, Takeji
- Abstract
Hepatitis B virus (HBV) replication has been shown to persist at low levels in the liver for decades, even in patients with resolved HBV infection. In these cases, reactivation of HBV and ensuing hepatitis during or after cytotoxic or immunosuppressive therapy is now recognized as de novo HBV-related hepatitis. The occurrence of de novo HBV-related hepatitis has become more frequent after the introduction of rituximab for the treatment of hematological disorders, such as malignant lymphomas. More alarmingly, reactivation can lead to fatal fulminant hepatic failure, indicating a need to establish guidelines to prevent the occurrence of de novo HBV-related hepatitis. It is possible that lamivudine prophylaxis and close surveillance of serum HBV DNA are effective in this regard. However, such measures are currently not available to hepatitis B surface antigen (HBsAg)-negative patients in Japan. A preliminary guideline for preventing HBV reactivation during and after cytotoxic or immunosuppressive therapies was made in 2008 by two collaborative study groups from the Japanese Ministry of Health, Labour, and Welfare, including measures not only for HBV carriers, but also for patients with resolved HBV infection. Since this recommendation is a tentative one, further testing and improvements are being planned. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
13. Late Reactivation of Hepatitis B Virus after Chemotherapies for Hematological Malignancies: A Case Report and Review of the Literature
- Author
-
Toshiki Yamada, Masahito Shimizu, Atsushi Suetsugu, Hisashi Tsurumi, Yasuhito Nannya, Junichi Sugihara, Shogo Shimizu, and Mitsuru Seishima
- Subjects
Male ,Hepatitis B virus ,Lymphoma ,medicine.medical_treatment ,Antineoplastic Agents ,Case Report ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,rituximab ,Immunity ,Internal Medicine ,medicine ,Humans ,de novo hepatitis ,Aged ,Chemotherapy ,Hepatitis B Surface Antigens ,business.industry ,General Medicine ,Cytotoxic chemotherapy ,medicine.disease ,Hepatitis B ,030220 oncology & carcinogenesis ,Hematologic Neoplasms ,Immunology ,030211 gastroenterology & hepatology ,Virus Activation ,business ,Complication - Abstract
Reactivation of hepatitis B virus (HBV) is a serious complication of immunosuppressive therapy and cytotoxic chemotherapy. The optimal duration of HBV-DNA monitoring for at-risk patients depends on the clinical features of reactivation, especially the range of potency from therapies to reactivation. We present a case of very late reactivation after chemotherapy for lymphoma and review previous reports of late reactivation cases. We also underscore the significance of developing an indicator for anti-HBV immunity which can be used to determine the optimal monitoring period.
- Published
- 2017
14. Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma.
- Author
-
Hara T, Oka K, Iwai N, Inada Y, Tsuji T, Okuda T, Nagata A, Komaki T, and Kagawa K
- Subjects
- Female, Hepatitis B Surface Antigens, Hepatitis B virus, Humans, Male, Middle Aged, Rituximab adverse effects, Virus Activation, Hepatitis B, Peripheral Blood Stem Cell Transplantation adverse effects
- Abstract
A 54-year-old woman underwent chemotherapy including rituximab and autologous peripheral blood stem cell transplantation (auto-PBSCT) for diffuse large B-cell lymphoma. Before the treatment, she exhibited a resolved hepatitis B virus (HBV) infection. She was diagnosed with HBV reactivation based on positive serum HBV-DNA test results, 55 months after her last treatment. Subsequently, he was treated with tenofovir alafenamide fumarate (TAF) therapy and her liver function improved. Patients undergoing chemotherapy including rituximab and auto-PBSCT are at a high risk of HBV reactivation. In such cases, careful and long-term observations may be required to detect HBV reactivation.
- Published
- 2021
- Full Text
- View/download PDF
15. Adult Living Donor Liver Transplantation Using Hepatitis B Core Antibody-Positive Grafts in Korea, a Hepatitis B-endemic Region
- Author
-
Myeong Jun Song, Joon Yeol Han, Si Hyun Bae, Chung Hwa Park, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang, U Im Chang, Hee Yeon Kim, and Dong Goo Kim
- Subjects
Hepatitis B virus ,HBsAg ,Liver transplantation ,Hepatology ,business.industry ,medicine.medical_treatment ,Liver, Pancreas and Biliary Tract ,Hepatitis B core antibody ,Gastroenterology ,virus diseases ,Hepatitis B ,Hepatitis b surface antigen ,medicine.disease ,medicine.disease_cause ,Virology ,Hepatitis b core antibody ,digestive system diseases ,Immunology ,medicine ,HEPATITIS B CORE ANTIBODY POSITIVE ,Original Article ,Living donor liver transplantation ,business ,De novo hepatitis - Abstract
Background/Aims The exclusion of hepatitis B core antibody (HBcAb)-positive donors from liver transplants (LTs) due to the risk of transmitting hepatitis B virus (HBV) does not appear to be practical in Korea, where hepatitis B is endemic. This study assessed the risk of de novo HBV infection in hepatitis B surface antigen (HBsAg)-negative LT recipients receiving a liver from HBcAb-positive donors. Methods Of 341 adult living donor LTs conducted at our institution between March 2001 and September 2008, 176 donors (51.6%) were HBcAb-positive, and 26 HBcAb-positive grafts were transplanted to HBsAg-negative recipients. The median follow-up time after LT was 41.9 months. Results Without anti-HBV prophylaxis, 2 out of 26 (7.7%) HBsAg-negative recipients who received grafts from HBcAb-positive donors developed de novo HBV infection 20 and 85 months after LT. These patients had been negative for all HBV serologic markers before transplantation. In both cases, there were no abnormalities in liver function tests upon diagnosis of de novo HBV infection. Conclusions De novo HBV infection from HBcAb-positive donors after LT does not appear to be of great concern in terms of the number of cases in Korea because high risk patients who are HBV-negative comprise only a small proportion of the recipients. However, HBV-naïve LT recipients still carry the risk of developing de novo HBV infection as in non-HBV endemic areas.
- Published
- 2011
16. Liver Transplantation Using Hepatitis B Core Antibody−Positive Grafts: Review and University of Tokyo Experience
- Author
-
Takemura, Nobuyuki, Sugawara, Yasuhiko, Tamura, Sumihito, and Makuuchi, Masatoshi
- Published
- 2007
- Full Text
- View/download PDF
17. Adult Living Donor Liver Transplantation Using Hepatitis B Core Antibody-Positive Grafts in Korea, a Hepatitis B-endemic Region.
- Author
-
Kim HY, Choi JY, Park CH, Song MJ, Jang JW, Chang UI, Bae SH, Yoon SK, Han JY, and Kim DG
- Abstract
Background/aims: The exclusion of hepatitis B core antibody (HBcAb)-positive donors from liver transplants (LTs) due to the risk of transmitting hepatitis B virus (HBV) does not appear to be practical in Korea, where hepatitis B is endemic. This study assessed the risk of de novo HBV infection in hepatitis B surface antigen (HBsAg)-negative LT recipients receiving a liver from HBcAb-positive donors., Methods: Of 341 adult living donor LTs conducted at our institution between March 2001 and September 2008, 176 donors (51.6%) were HBcAb-positive, and 26 HBcAb-positive grafts were transplanted to HBsAg-negative recipients. The median follow-up time after LT was 41.9 months., Results: Without anti-HBV prophylaxis, 2 out of 26 (7.7%) HBsAg-negative recipients who received grafts from HBcAb-positive donors developed de novo HBV infection 20 and 85 months after LT. These patients had been negative for all HBV serologic markers before transplantation. In both cases, there were no abnormalities in liver function tests upon diagnosis of de novo HBV infection., Conclusions: De novo HBV infection from HBcAb-positive donors after LT does not appear to be of great concern in terms of the number of cases in Korea because high risk patients who are HBV-negative comprise only a small proportion of the recipients. However, HBV-naïve LT recipients still carry the risk of developing de novo HBV infection as in non-HBV endemic areas.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.